Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 96.03M | 99.36M | 75.80M | 141.12M | 137.39M | 95.36M |
Gross Profit | 16.50M | 23.84M | 13.32M | 52.12M | 47.41M | 30.27M |
EBITDA | -8.55M | -338.00K | -8.78M | 30.12M | 25.10M | 11.63M |
Net Income | -18.34M | -11.62M | -17.88M | 15.81M | 14.57M | 3.24M |
Balance Sheet | ||||||
Total Assets | 333.48M | 339.31M | 358.70M | 370.07M | 332.44M | 298.86M |
Cash, Cash Equivalents and Short-Term Investments | 31.58M | 22.83M | 39.89M | 44.29M | 42.18M | 72.84M |
Total Debt | 54.91M | 49.78M | 55.73M | 48.88M | 16.54M | 13.23M |
Total Liabilities | 87.31M | 84.41M | 89.56M | 80.33M | 52.21M | 43.33M |
Stockholders Equity | 185.04M | 192.77M | 203.99M | 221.61M | 211.53M | 192.62M |
Cash Flow | ||||||
Free Cash Flow | -8.54M | -17.88M | -7.07M | -37.23M | -32.95M | -13.99M |
Operating Cash Flow | -6.65M | -12.11M | 3.40M | -8.77M | -3.31M | 5.87M |
Investing Cash Flow | -1.32M | -4.45M | -2.60M | -25.22M | -38.81M | -16.42M |
Financing Cash Flow | 4.35M | -536.00K | 8.61M | 38.03M | 5.72M | 52.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
63 Neutral | $33.91B | 5.95 | -11.88% | 1.83% | 5.33% | -18.39% | |
56 Neutral | $128.77M | ― | -33.15% | ― | -5.73% | 47.83% | |
55 Neutral | $100.33M | ― | -9.50% | ― | 21.44% | -8.49% | |
51 Neutral | $182.21M | ― | 1716.04% | ― | ― | ― | |
51 Neutral | $68.85M | 40.38 | -47.90% | ― | -16.52% | -46.13% | |
49 Neutral | $70.88M | ― | 17.45% | ― | 94.76% | -146.39% | |
44 Neutral | $36.46M | ― | -2911.20% | ― | -47.93% | -37.78% |
On July 9, 2025, AXT, Inc. announced a preliminary revenue range for the second quarter of 2025, expecting revenues between $17.5 and $18 million, which is below the previously guided $20 to $22 million. This shortfall is attributed to slower issuance of export control permits for gallium arsenide products and weaker demand in China. Despite these challenges, AXT reported increased AI-related demand for indium phosphide in China and received its first export control permits for indium phosphide late in the quarter. The company remains focused on improving gross margins, expecting them to be in the high single digits for Q2 2025.
The most recent analyst rating on (AXTI) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on AXT stock, see the AXTI Stock Forecast page.
On June 11, 2025, Beijing Tongmei Xtal Technology, a subsidiary of AXT, Inc., received its initial export permits from the Ministry of Commerce of the People’s Republic of China to resume shipping indium phosphide substrates to certain customers. This development follows the export controls imposed on February 4, 2025, by Chinese authorities on materials including indium, impacting the company’s operations and market positioning.
The most recent analyst rating on (AXTI) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on AXT stock, see the AXTI Stock Forecast page.
On May 15, 2025, AXT held its Annual Meeting of Stockholders, where 69% of the total shares entitled to vote were represented. During the meeting, Christine Russell was elected as a Class III director for a three-year term, the executive compensation was approved on an advisory basis, the 2025 Equity Incentive Plan was approved, and BPM LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (AXTI) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on AXT stock, see the AXTI Stock Forecast page.